By working in close partnership with customers, Schreiner MediPharm develops in-depth knowledge of their production p

Crystal Lake, Illinois, October 29, 2020 — AptarGroup, Inc. (NYSE:ATR) today reported third quarter results for 2020 and provided an update related to COVID-19 including the Company’s continued supply of essential products for critical industries.

Third Quarter 2020 Summary

Reported sales increased 8%, including positive effects of currency translation rates and recent acquisitions, and core sales increased 2%
Strong reported and core growth in our Pharma segment
Core sales growth in the food, personal care and home care markets
Sales to the beauty and beverage markets continue to be impacted by COVID-19 pandemic
Recent acquisitions are performing well
Reported earnings per share totaled $0.95 (an increase of 12% compared to the prior year)
Adjusted earnings per share totaled $1.00 (an increase of 3% compared to the prior year)
Reported net income totaled $64 million (an increase of 12% compared to the prior year)
Adjusted EBITDA totaled $157 million (an increase of 7% compared to the prior year)
Cash flow from operations was $381 million in the first nine months of 2020 (a slight increase over the prior year)
Free cash flow was $208 million in the first nine months of 2020 (an increase of 8% compared to the prior year)
Declared quarterly dividend of $0.36 per share
 

COVID-19 Update
“As we continue to rigorously monitor the ongoing COVID-19 situation across the globe, our
priorities remain the health and safety of our employees and continued production for our customers,” said
Stephan Tanda, Aptar President and CEO. “Millions of people around the world rely on Aptar solutions to
dispense the medicines and products they need and we are delivering on our promises to our customers.”
During the pandemic, we have continuously adapted our safety and cleaning procedures and remote
working protocols in accordance with the legislation or regulations applicable to each of our facilities. 

Third Quarter Results
For the quarter ended September 30, 2020, reported sales increased 8% to $759 million
compared to $701 million in the prior year. Core sales, excluding the impacts from changes in currency
exchange rates and acquisitions, increased approximately 2%.

Investor Relations Contact:         Media Contact:
Matt DellaMaria                          Katie Reardon
matt.dellamaria@aptar.com        katie.reardon@aptar.com
815-479-5530                           815-479-5671

The applicants were judged on five categories: innovation, functionality, differentiation, design, and expression of

Brenntag (ISIN DE000A1DAHH0), the global market leader in chemical and ingredients distribution, and CheMondis (www.chemondis.com), the leading B2B online marketplace for chemicals in Europe, announce a first cooperation. Brenntag and CheMondis plan to jointly accelerate digital sales and marketing for the chemical industry. Both companies recognize the increasing importance of online sales channels for the chemical industry and agreed to collaborate in this field.

The collaboration will start with making Brenntag’s leading portfolio for Paints & Coatings and Adhesives & Sealants gradually available for online purchase on theMondis in the German market.

“Over the last two years Brenntag has steadily built our Brenntag Connect ecommerce platform. The platform is now live in most of our mature markets. We see a strong upward trend in online business and with this complementary cooperation we extend our digital channels further,” Maarten Stramrood, CDO at Brenntag, added. “Our collaboration with CheMondis will provide our current and potential customers an even broader choice.”

“At CheMondis we are excited to welcome the world’s leading distributor Brenntag as a new partner. It is a strong sign that online sales are becoming an increasingly important strategic component in the chemical industry,” said Sebastian Brenner, Managing Director of CheMondis. “Customers in our industry are demanding an online buying experience and CheMondis provides for that need.”

About CheMondis:
CheMondis was founded in 2018 out of LANXESS as an independent startup and has since then established the leading open B2B marketplace for Chemicals in Europe with more than 3,200 active companies and about 50,000 products listed. CheMondis offers sellers of chemical products (manufacturers and distributors) a state-of-the-art online sales channel, offering a full digital customer journey, professional online marketing support and data-driven analytics. Buyers have used CheMondis for several thousand digital transactions already.

About Brenntag:
Brenntag is the global market leader in chemical and ingredients distribution. We connect our suppliers and customers in value-adding partnerships. Our almost 17,500 employees provide tailor-made application, marketing and supply chain solutions. Technical and formulation support, market, industry and regulatory expertise as well as advanced digital tools are just some examples of our services that are aiming to create an excellent customer experience. Our full-line portfolio comprises specialty and industrial chemicals and ingredients of a world-class supplier base. Building on its long-standing experience, unmatched global reach and local excellence, Brenntag works closely alongside its partners to make their business more successful. We are committed to contribute towards greater sustainability in our own business and the industries we serve, and to achieve sustainable profitable growth. Headquartered in Essen (Germany) and with regional headquarters in Philadelphia, Houston and Singapore, Brenntag operates a unique global network with more than 640 locations in 77 countries. The company generated sales of EUR 12.8 billion (USD 14.4 billion) in 2019. Brenntag shares are traded at the Frankfurt Stock Exchange (BNR).

Management:                                                       Media Relations:
Sebastian Brenner                                                Caroline Sajonz

CheMondis GmbH                                                CheMondis GmbH
Zeppelinstraße 9                                                  Zeppelinstraße 9
50667 Köln                                                          50667 Köln
Germany                                                              Germany
Telephone: +49 151 74 61 34 30                        Telephone: +49 151 233 74 252
E-Mail: sebastian.brenner@chemondis.com          E-Mail: caroline.sajonz@chemondis.com
www.chemondis.com                                            www.chemondis.com

This acquisition strengthens Nemera’s proprietary product offering and establishes operations footprint in Eastern Europe.

Nemera today announced that they have entered into an agreement to acquire Copernicus. Copernicus, based in Szczecin Poland, specializes in the development and manufacturing of injection devices. Their range of reusable and disposable pen injectors are tailored for the treatment of several chronic pathologies.

Founded in 2004, Copernicus is regarded as one of the most valued innovative companies in the Polish health sector. They provide a comprehensive range of services in the introduction of modern and intuitive parenteral drug delivery devices.

This acquisition reinforces Nemera’s vision of becoming the most patient-centric drug device combination solutions company. It bolsters our small series production capabilities, R&D expertise and parenteral product offering. Most importantly it expands our overall proprietary product portfolio. Copernicus’ fast and agile clinical manufacturing, adapted for small series, complements Nemera’s historical large scale manufacturing capabilities. Furthermore, Copernicus’ marketed reusable pen injectors are of great value from a sustainability standpoint.

With this acquisition we establish an operations footprint in Eastern Europe. In order to accompany Copernicus’ solid forecasted growth we will work together to build a new state-of-the-art manufacturing facility in Szczecin, Poland.

Marc Hämel, CEO of Nemera said, “This acquisition is a great strategic and cultural fit for us. Copernicus’ strong focus on patient needs aligns perfectly with our purpose of
always putting the patient at the center of everything we do. We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future”.

“Nemera’s unaltered focus on patient needs and passion to develop combination product solutions of the future convinced us that this was the right next step. We’re
thrilled to join Nemera and together make products that truly improve patients’ lives” added Alberto Lozano, CEO of Copernicus.

About Nemera
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera offers a comprehensive portfolio of products and services across ophthalmology, nasal, inhalation, dermal, transdermal and parenteral delivery. Nemera’s vision is to be the most patient-centric drug delivery device company. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health. Nemera’s Insight Innovation Center, with offices in North America and Europe, provides consultative services to support your overall device strategy. Providing user research, Human Factors, User Experience design, and Design for manufacturing, ourInsight Innovation Center helps customers navigate their device strategy for both novel and platform solutions. Users are at the center of everything that we do in our effort to always put patients first. For more information, visit www.nemera.net.

Press contact
Niyati Sapatnekar
Communications Manager
niyati.sapatnekar@nemera.net

Stevanato Group high-speed visual inspection machines will support biologic and vaccine programs at Catalent manufacturing sites in the US and Italy.
Piombino Dese (PD), Italy – October 27, 2020 –  Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for drug delivery systems has expanded its longstanding collaboration with Catalent, the US-based leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, to include the provision and accelerated delivery of advanced visual inspection systems to help with potential solutions to the pandemic.

Stevanato Group's integrated capabilities serving the pharma industry and its proven expertise in visual inspection will allow the company to support Catalent and its customers' biologics and sterile injectable products.

Within the context of an expanded partnership, Catalent has ordered Plus 400 LKD automatic and PWL semi-automatic visual inspection machines from Stevanato Group. Catalent will install the equipment at its sites in Bloomington, Indiana, and Anagni, Italy, to support various customer programs. The quality assurance solutions feature advanced technologies to reliably inspect biologics and sterile injectables, maximizing the detection rate while keeping false rejects low. A nod to the expediency required in the current environment, Stevanato Group is accelerating delivery of the high precision and high throughput equipment by several months.

“Catalent appreciates Stevanato Group’s commitment to delivering these vital inspection machines to our sites ahead of schedule,” says Dominick Marino, Vice President of Global Procurement at Catalent. “This added capability will increase the speed in which we package and supply important medicines for our customers and patients.”

“We understand what is at stake, and our engineers are committed to delivering high-performance inspection machines ahead of schedule to meet Catalent’s needs and expectations,” said Raffaele Pace, Engineering Vice President of Operations, Stevanato Group.

About Stevanato Group

Established in 1949, Stevanato Group is the world’s largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historical brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment. The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, Stevanato Group can offer an unprecedented set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership. For more information, please visit www.stevanatogroup.com.

For more information, please contact:

Christopher Dale,

Director of PR and Communications at Turchette,

cdale@turchette.com

Rotoflex has successfully developed and installed a highly customized booklet label machine for American printer JH Bertrand Inc. 

Since 1981, JH Bertrand Inc. has focused production on booklet labels that expand copy space on CPG. Pharma, chemical, and consumer-industrial companies commonly use extended-content labels to comply with government regulations, translate information, detail product use directions, include promotional coupons and rebates, and to protect themselves from litigation.

Dedicated to handling a full range of booklet label sizes, the Rotoflex machine can process booklet labels with as many as 96 pages of text and graphics, a breakthrough solution in the multi-layer label market. 

“JH Bertrand is a very innovative company. Our focus is booklet labels, so we are always trying to figure out new ways to make them. Many of our constructions need a gentle web path due to thickness and other factors. Recently, we had an idea for a straighter web path, so we presented it to the great people of Rotoflex. They took our ideas and turned it into a one-of-a-kind machine that we absolutely love,” said Jeff Bertrand, CEO of JH Bertrand Inc.

The machine is based on Rotoflex VSI platform and features a short and simple web path using large idlers to handle challenging booklet applications. A custom design for the inspection system area keeps the booklet labels intact when running underneath the camera. Additional unique aspects include a laterally moving guided unwind, straight-through special draw station with larger diameter roll, and a soft rubber nip roll with adjustable nipping distance and pressure -with a provided segmented nip roll if running more than several rows across the web.

“This customized solution we designed for JH Bertrand, a long-standing Rotoflex customer, is an example of our advanced technology developments and expertise in booklet material,” said Manohar Dhugga, Rotoflex VP of Operations. “We are open to working with label printers and converters in designing bespoke label finishing machines to accommodate unique production needs, and we have a team of engineers on-site with years of design and finishing technology expertise,” added Dhugga.

JH Bertrand Inc. is not only satisfied with the product itself, but also with the relationship established with Rotoflex over the years. “Since the very beginning, Rotoflex has been a truly wonderful partner. We get a lot of value from the relationship and enjoy doing business with the company very much,” concludes Bertrand.  

About Rotoflex

With more than 8000 installations globally, Rotoflex is a world leader in inspection, slitting, rewinding, and die-cutting equipment. Rotoflex looks beyond the machine to the ultimate needs of its customers. We work in partnership to serve your unique, specific requirements. Our customer-driven approach has made us the finishing partner of choice – for over 45 years. Rotoflex equipment is supported globally by the largest OEM Customer Support team in the industry. 

A proud brand of Mark Andy Inc., (markandy.com), Rotoflex is an important aspect of the company’s Total Solution Partner strategy. The business is headquartered in Mississauga, Ontario, Canada, with sales and distribution offices worldwide.

For more information about Rotoflex, visit www.rotoflex.com

For additional media information,

please contact

Amanda Flower

amanda.flower@markandy.com /

+1 636 681 9036.

Stevanato Group high-speed visual inspection machines will support biologic and vaccine programs at Catalent manufacturing sites in the US and Italy.

Piombino Dese (PD), Italy – October 27, 2020 – Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for drug delivery systems has expanded
its longstanding collaboration with Catalent, the US-based leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and
gene therapies, and consumer health products, to include the provision and accelerated delivery of advanced visual inspection systems to help with potential solutions to the pandemic.

Stevanato Group's integrated capabilities serving the pharma industry and its proven expertise in visual inspection will allow the company to support Catalent and its customers' biologics and sterile injectable products.

Within the context of an expanded partnership, Catalent has ordered Plus 400 LKD automatic and PWL semi-automatic visual inspection machines from Stevanato Group. Catalent will install the
equipment at its sites in Bloomington, Indiana, and Anagni, Italy, to support various customer programs. The quality assurance solutions feature advanced technologies to reliably inspect
biologics and sterile injectables, maximizing the detection rate while keeping false rejects low. A nod to the expediency required in the current environment, Stevanato Group is accelerating
delivery of the high precision and high throughput equipment by several months.

“Catalent appreciates Stevanato Group’s commitment to delivering these vital inspection machines to our sites ahead of schedule,” says Dominick Marino, Vice President of Global
Procurement at Catalent. “This added capability will increase the speed in which we package and supply important medicines for our customers and patients.”

“We understand what is at stake, and our engineers are committed to delivering high- performance inspection machines ahead of schedule to meet Catalent’s needs and expectations,”
said Raffaele Pace, Engineering Vice President of Operations, Stevanato Group.

For more information, please contact:
Christopher Dale,

Director of PR and Communications at Turchette,

cdale@turchette.com

About Stevanato Group

Established in 1949, Stevanato Group is the world’s largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group
has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and
diagnostic industries: from glass containers with its historical brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment. The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, Stevanato Group can offer an unprecedented set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership. For more information, please visit www.stevanatogroup.com.

Launchworks CDMO added to FDA list of approved vendors for validating and distributing VTM, in accordance with COVID-19 EUA Transport Media Policy.

LaunchWorks CDMO, a contract development and manufacturing company serving the life science market, has been approved to manufacture and distribute Viral Transport Media, in
accordance with Section IV.B of the FDA’s COVID-19 Transport Media Policy. The company’s Viral Transport Media is available in the form of bulk tubes, large volume containers and a
specimen kit, which will include a tube of sterile LaunchWorks VTM, a biohazard bag and an absorbent bag. Additional options include Nylon-flocked NP swab, Barcode or QP-coded
labels, patient card, and a UN 3373 return box.

The Viral Transport Media is a new addition to the LaunchWorks suite of products and service offerings. As an FDA-registered ISO 13485 certified company, LaunchWorks is a
division of Integreon Global, which has supported LaunchWorks’ expansion in molecular diagnostics with the additions of new service offerings, including embarking on an
automation program designed to help its customers be more competitive. Recently, a significant portion of the company’s efforts have involved the response to the COVID-19
crisis, and the development of Viral Transfer Media is a valuable addition.

“We’re grateful to contribute to the fight against the pandemic, and to add this important component to our product portfolio,” says Jeff Kelly, General Manager of LaunchWorks
CDMO. “Our team has worked hard to bring this product to market, and the addition brings us one step closer to offering an end-to-end solution for our customers supporting the fight
against COVID-19.

“This reinforces the LaunchWorks’ commitment to continue to expand and support the world’s changing needs due to the pandemic,” he continued. “The Launchworks service suite
ranges from package design to formulation, filling, and fulfillment, making us uniquely positioned to help companies translate their science into commercial products. We take
pride in our ability to contribute to the resulting improvement in world health.”

###

About LaunchWorks
LaunchWorks is a winning team of innovative, experienced, and knowledgeable contract manufacturing experts with a track record of turning complex life science ideas into high-
quality products on-time and on-budget. They are committed to accelerating life science product commercialization by optimizing every step of the manufacturing process in order to
create high-quality products for our customers that reach the market and the people that need it, safely and quickly. For more information visit www.launchworkscdmo.com

About Integreon Global
Founded in 1990, Integreon is a complete packaging solutions provider dedicated to providing goods and services to maintain the integrity of our clients’ products. Our team
includes a full complement of engineers, designers, and manufacturing specialists with the collective skills, gathered in one close-knit organization, to assure easy access to leading
experts. For more information visit www.integreonglobal.com

client: LaunchWorks
contact: Christopher Dale
Turchette Agency
(973) 227-8080, ext. 116
cdale@turchette.com

1. Originality in Cloth Bag

As travel restrictions & social-distancing guidelines remain in place, many consumers are beginning to take beaut

After learning about Aptar from a recent Wall Street Journal article, producers at the US national news program calle

At Aptar, we are committed to our people, and to creating a fair and equitable workplace where everyone can thrive.

Since its establishment in 1995, the Agency has harmonised and improved the evaluation of medicines, stimulated innov

Also, total sales of certain veterinary antimicrobial agents belonging to antibiotic classes that are considered crit

Crystal Lake, Illinois – September 24, 2020 - Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions, is pleased to announce its Platinum
Sponsorship of the CPhI Festival of Pharma, to be held online from October 5-16, 2020. A long-time strategic partner and supporter of CPhI events globally, Aptar Pharma will unveil a
new, state-of-the-art interactive booth at this virtual event that captures the essence of an inperson experience during these unprecedented times.

Enhancing the Virtual Visitor Experience
Part of their Company Showcase, which will be available to visitors of the event for 12 months, Aptar Pharma’s virtual booth will bring to life why it is the go-to drug delivery partner,
unlocking value for customers throughout their product development journey.

Rich in content, featuring multi-media videos, brochures, scientific publications and other experiences, Aptar Pharma’s life-like booth will give visitors the opportunity to explore,
discover and interact with their broad range of complete product and service solutions, further enhancing the virtual experience.
Carolyn Penot, Director of Operational Marketing at Aptar Pharma commented: “As a longstanding partner of CPhI, we wanted to show our full support for their new Festival of
Pharma digital event and are proud to be a Platinum Sponsor. Aptar Pharma’s virtual experience gives us the opportunity to continue to support our worldwide customers, in the
absence of in-person events this year, in a new and engaging way.”

Transforming Ideas into Opportunities
An expert in transforming ideas into opportunities, Aptar Pharma will showcase in 3D its
latest range of innovations, including:
 PureHale® - a portable and ready-to-use drug delivery solution designed for upper respiratory care
 Connected Add-On Device for metered-dose inhalers (MDIs)
 Unidose Trainer Device - a pioneering patient onboarding device from Noble, an Aptar Pharma company, that was used for the first and only U.S. FDA-approved
nasal rescue treatment for seizure activity, and is based on Aptar Pharma’s UDS
device.

An Essential Industry Partner During COVID-19
Aptar Pharma has been an essential partner to industry during the COVID-19 pandemic, ensuring the supply of its portfolio of drug delivery solutions that improve and save lives,
which is especially important for customers and patients as the pandemic continues to dominate the healthcare environment.
Discover how Aptar Pharma services can accelerate and derisk drug development and how its proven solutions are enabling the rapid deployment Covid-related vaccines and
treatments for customers.

Recognizing Innovation Excellence
Aptar Pharma is proud to be a Finalist for four Digital CPhI Pharma Awards at this year’s
event:
• Excellence in Pharma: Drug Delivery Devices - PureHale® Portable Upper
Respiratory Device
• Excellence in Pharma: Packaging - Activ-Blister™ by Aptar CSP Technologies
• Excellence in Pharma: Packaging - Noble's Unidose Nasal Training Kit for
Nayzilam®
• Excellence in Pharma: Innovation in Response to COVID-19 - ActivShield™ by
Aptar CSP Technologies.
The winners of the Digital CPhI Pharma Awards will be announced during a live online
ceremony on 13 October at 16:00 (CET).

Sharing Expertise with a Global Audience
As part of the CPhI Festival of Pharma conference program, two Aptar Pharma experts will share critical industry insights and expertise during the two week event: 
 On October 6 at 11:00 CET, Aptar Pharma will sponsor “The Future of Drug Delivery” Keynote Speaker webinar on patient-focused drug design, which will
be introduced by Tim McLeroy, Executive Director of Marketing and Patient Services at Noble, an Aptar Pharma company. Tim’s presentation will highlight the
importance of remote patient training, onboarding and monitoring – which has increased during COVID-19 - for improving patient adherence and outcomes.

 On October 8 at 15:30 CET, Sai Shankar, Vice-President Global Digital Healthcare Systems at Aptar Pharma, will participate in a live panel discussion
entitled “Trends in Pharma Packaging, Administration & Drug Delivery Devices”. As part of his panel discussion, Sai will present on the “Increasing
Importance of Connected Devices and Digitalization in Post Pandemic R&D”.

CPhI Festival of Pharma visitors can register to attend these key presentations via the event
website.

Enlarging Access to Global Pharma Expertise
Thanks to the virtual format at CPhI Festival of Pharma, Aptar Pharma will be providing expanded access to its experts from around the world and across all delivery routes via online meeting slots, which provide an excellent meeting or networking opportunity. Both new and existing customers can book their meetings by visiting the Aptar Pharma Company
Showcase.

Gael Touya, President of Aptar Pharma, commented: “CPhI plays a pivotal role in the global pharma industry, providing the perfect platforms to meet, network and ultimately do business
together. This year, we are happy to support CPhI with its Festival of Pharma and are proud to have created a virtual platform that will deliver the highest quality visitor experience and
demonstrate to the industry what makes Aptar Pharma the go-to drug delivery expert.”

The CPhI Festival of Pharma event will bring the global pharma industry together, and expect
to welcome over 20,000 attendees and 700+ exhibitors from around the world, offering bestin-class networking, learning and sourcing opportunities – from the comfort of the home
office.

Register now at https://www.cphi.com/festival-of-pharma/.
About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active packaging solutions. Aptar uses insights, design, engineering and science to create dosing, dispensing and protective packaging technologies for the world’s leading brands, in turn making a
meaningful difference in the lives, looks, health and homes of millions of people around the world. Aptar’s innovative solutions and services serve a variety of end markets including
pharmaceutical, beauty, personal care, home, food and beverage. The company is headquartered in Crystal Lake, Illinois and has 14,000 dedicated employees in 20 countries.
For more information, visit www.aptar.com.

# # #
Media Contact:
Carolyn Penot
Aptar Pharma
+33 6 37 36 76 84
carolyn.penot@aptar.com

With the need for on-the-go anti-bacterial products on the rise, it is common for brand owners to find themselves in

The benefits of AdhereIT™ include improved drug management, enriched patient experiences and enhanced patient outcomes

Crystal Lake, Illinois and Orlando, Florida, October 5, 2020 - Noble and Aptar Pharma are pleased to announce the launch of AdhereIT™ - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT™ is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms. This launch is an important advancement for Noble, an Aptar Pharma company, whose mission is to foster healthy outcomes for patients who self-administer their therapies, partnering with pharma and biotech companies to provide robust training devices and onboarding programs.

Adherence to prescribed biologics is a significant challenge. A recent report in the Journal of the American Academy of Dermatology reported that 45% of studied patients suffering from
psoriasis discontinue their treatments. The reasons include insufficient training or time with an instructor, lack of confidence during the self-injection process, and feelings of high anxiety and lack of control. COVID-19 has contributed to the increase utilization of telemedicine and remote healthcare, which has even further complicated this challenge by reducing healthcare
professional (HCP) training opportunities with patients.

AdhereIT™ is part of the digital ecosystem that enables patients to gain control and confidence over their at-home drug delivery while easing the anxiety associated with selfinjecting. AdhereIT™ integrates with the existing software applications developed by the Digital Healthcare team at Aptar Pharma by pairing a patient’s autoinjector via Bluetooth
technology to their mobile phone. The device – available in two design options to accommodate dexterity for a one-handed or two-handed injection process – precisely detects
an injection event and provides real-time visual, audio and haptic feedback about whether the injection was performed correctly. The AdhereIT™ onboarding platform also allows
HCPs to monitor their patients’ therapeutic performance via a smart analytical dashboard, providing valuable patient-specific adherence behavior information.

“We are excited to welcome Noble’s AdhereIT™ connected onboarding platform into the suite of Aptar Pharma’s Digital Healthcare solutions. This innovative technology further
enhances our ability to improve patients’ lives by creating a seamless integration of injectable products into our disease management offerings,” said Adam Shain, Director of Business
Development for Digital Healthcare, Aptar Pharma.

Noble developed AdhereIT™ in partnership with Aptar Pharma, who has made significant investments in digital healthcare over the past three years to actively develop a portfolio of
disease management platforms and connected device solutions across dermal, pulmonary, nasal, ophthalmic and injectable routes of administration.

“Connected medical devices represent the future of healthcare for patients, pharmaceutical companies, health insurers and HCPs, playing a vital role in the remote tracking and
treatment of chronic illnesses, and delivering a range of benefits that include improved drug management, enriched patient experiences and enhanced patient outcomes,” said Tim
McLeroy, Noble’s Executive Director of Marketing & Patient Services. “The connectivity of digital technology solutions like AdhereIT™ also create market differentiation and enable
value-based contracting for biopharmaceutical companies and medical device manufacturers to survive in a competitive and challenging marketplace.”

About Noble
Noble is focused on fostering healthy patient outcomes for those who self-administer drug therapies through the development of robust training devices and onboarding solutions for
the world’s top pharma brands and biotech companies. Noble manufactures and commercializes training devices that mimic the exact feel, force and function of drug delivery
devices such as autoinjectors, prefilled syringes, onbody, nasal and pulmonary devices in order to increase patient adherence and confidence, and decrease usage errors. Noble was
founded in 1994 and is based in Orlando, Florida. Noble is an Aptar Pharma company. For more information, visit www.gonoble.com.

About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active packaging solutions.
Aptar uses insights, design, engineering and science to create dosing, dispensing and protective packaging technologies for the world’s leading brands, in turn making a
meaningful difference in the lives, looks, health and homes of millions of people around the world. Aptar’s innovative solutions and services serve a variety of end markets including
pharmaceutical, beauty, personal care, home, food and beverage. The company is headquartered in Crystal Lake, Illinois and has 14,000 dedicated employees in 20 countries.
For more information, visit www.aptar.com.
# # #

Media Contact – Aptar Pharma
Carolyn Penot
Aptar Pharma
+33 6 37 36 76 84
carolyn.penot@aptar.com

Media Contact – Noble
Carolyn Reis
APR
+1 407 590 0251
carolyn@ReisCorporatePR.com